Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
Journal: European urology
Published: August 15, 2019
The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 13, 2016
Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.
Journal: The Journal of clinical endocrinology and metabolism
Published: October 27, 2015
Oxandrolone Augmentation of Resistance Training in Older Women: A Randomized Trial.
Journal: Medicine and science in sports and exercise
Published: April 23, 2015
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Journal: The Lancet. Oncology
Published: February 22, 2015
A Phase 1, Randomized, Single-Dose Crossover Pharmacokinetic Study to Investigate the Effect of Food Intake on Absorption of Orteronel (TAK-700) in Healthy Male Subjects.
Journal: Clinical pharmacology in drug development
Published: February 17, 2015
Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies.
Journal: The Journal of clinical endocrinology and metabolism
Published: April 26, 2014
Health-related quality of life in advanced prostate cancer and its treatments: biochemical failure and metastatic disease populations.
Journal: Clinical genitourinary cancer
Published: March 28, 2014
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 15, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026